Brian joined F-Prime Capital in 2018 and focuses primarily on investments in the biopharmaceutical and medical technology sectors. Prior to joining F-Prime, Brian was an engagement manager at McKinsey and Company, where he advised pharmaceutical and medical technology companies on business development, R&D, and strategy topics.
Brian holds a Ph.D. in immunology from Yale University and received his B.S. in biochemistry from the University of Notre Dame.
ABK Biomedical is organized to research, develop and commercialize breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. Specifically, ABK holds intellectual property in the focus area of inorganic polymer microspheres, targeted at the growing field of embolotherapy within the Interventional Radiology/Interventional Oncology medical disciplines. The company possesses advanced intellectual capital and its own R&D and manufacturing facilities for developing and commercializing unique, breakthrough embolotherapy products. Learn more at www.abkmedical.com.
Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Learn more at www.avalynpharma.com.
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Learn more at www.bicara.com
J-Pharma is a clinical stage biopharmaceutical company with a mission to create and develop novel pharmaceuticals. J-Pharma is conducting trials in Japan for advanced stage cancer patients. Learn more at j-pharma.com.
Rallybio (NASDAQ: RLYB) is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Learn more at www.rallybio.com.
RIGImmune is a platform biopharmaceutical company developing a novel investigational class of RNA immunotherapies termed “SLRs” for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The RIGImmune development candidates act to specifically modulate RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The lead development candidate at RIGImmune is RIG-101.
The company was co-founded by the prominent Yale University professors, Anna Marie Pyle, Ph.D. and Akiko Iwasaki, Ph.D., who currently serve as scientific advisors to the company. Dr. Pyle co-discovered the RIG-I receptor family and conducted many of the first structural and biochemical investigations on the cytosolic protein, RIG-I. Dr. Pyle is also a specialist in RNA structure and design. She designed the stem-loop RNA therapeutics (SLR) for selective targeting of RIG-I using crystal structure data of RIG-I complexed with RNA and developed them as antitumor and anticancer compounds in collaboration with Dr. Iwasaki, whose expertise in mucosal immunity has been highly sought during the COVID-19 pandemic.
RIGImmune is a UConn Technology Incubation Program (TIP) company located in Farmington, CT, was founded by Yale scientists, and has an experienced management team of successful biotech entrepreneurs and world-renowned scientists. Learn more at rigimmune.com.